BoomRx, a US-based pharmaceutical technology platform, announced on Friday that it is launching its centralised ordering platform directly to the anti-aging community at A4M's Longevity Fest 2025 in Las Vegas.
The company says that the portal consolidates the prescribing process into one seamless platform, connecting clinics and medical practices to a broad network of regulated 503A and FDA-registered 503B outsourcing facilities, as well as brand medications, through one centralised system.
Built to eliminate the inefficiencies of managing multiple pharmacy portals, state-by-state shipping rules, and fragmented pricing, BoomRxis claimed to enable med spas, wellness clinics, telemedicine providers, hormone-therapy practices, and other physician offices to access a wide portfolio of medications including those for weight loss, peptides, testosterone replacement therapy (TRT), bioidentical hormone replacement therapy (BHRT), erectile disfunction (ED), hair loss, and dermatology, through a single secure portal supporting shipping to all 50 states. The platform also provides transparent pricing and access to extended beyond-use dating (BUD) where available, based on product and formulation.
Kurt Lunkwitz, BoomRx president, said, Providers today are overwhelmed by the operational burden of managing multiple pharmacy relationships, contracts, shipping restrictions and fluctuating pricing. BoomRx removes that friction entirely. With one secure portal, providers can source 503A or 503B compounded preparations and brand medications nationally, reduce administrative time, get competitive pricing, lower shipping costs, and focus on what matters most patient care and practice growth.
Amgen's UPLIZNA receives US FDA approval
FDA grants priority review to Bristol Myers Squibb's Opdivo regimen for advanced Hodgkin lymphoma
Zydus Lifesciences enters licence and supply partnership with Formycon
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
J & D Pharmaceuticals' investigational therapy for HCC receives US FDA Orphan Drug Designation
FDA lifts partial clinical hold on Vanda Pharmaceuticals' tradipitant for motion sickness
TransThera publishes clinical results from US-based Phase 2 trial of tinengotinib in CCA
Hope Medicine wins FDA Fast Track Designation for HMI-115 in endometriosis
MED-EL cochlear implant FDA approved for children 7 months and older
Bayer launches Phase IIa trial of BAY 3401016 for Alport Syndrome